Treatment persistence and compliance with medications for chronic obstructive pulmonary disease - Wikidata - wikimedia - TriplyDB

Treatment persistence and compliance with medications for chronic obstructive pulmonary disease

Treatment persistence and compliance with medications for chronic obstructive pulmonary disease

http://www.wikidata.org/entity/Q37212357

about

Ten years of tiotropium: clinical impact and patient perspectives Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline.Management of asthma and chronic obstructive pulmonary disease with combination inhaled corticosteroids and long-acting β-agonists: a review of comparative effectiveness research.The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD.Treatment evolution after COPD diagnosis in the UK primary care setting.Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasone Characteristics of patients with COPD newly prescribed a long-acting bronchodilator: a retrospective cohort study.Evaluating the cost-effectiveness of tiotropium versus salmeterol in the treatment of chronic obstructive pulmonary disease.Early impact of treatment with tiotropium, long-acting anticholinergic preparation, in patients with COPD - real-life experience from an observational study.Impact of multiple-dose versus single-dose inhaler devices on COPD patients' persistence with long-acting β₂-agonists: a dispensing database analysis Frequency and risk factors of COPD exacerbations and hospitalizations: a nationwide study in Greece (Greek Obstructive Lung Disease Epidemiology and health ecoNomics: GOLDEN study).Optimizing safety of COPD treatments: role of the nurse practitioner.Health behaviors and their correlates among participants in the Continuing to Confront COPD International Patient Survey.Safety, tolerability and risk benefit analysis of tiotropium in COPD.A multicenter, retrospective study of patients with pulmonary arterial hypertension transitioned from parenteral prostacyclin therapy to inhaled iloprost.Long-acting bronchodilator therapy for the treatment of chronic obstructive pulmonary disease.Effectiveness of a pharmacist-driven intervention in COPD (EPIC): study protocol for a randomized controlled trial.Diagnosis and management of asthma in older adults.Estimating the economic consequences of an increased medication adherence due to a potential improvement in the inhaler technique with Spiromax® compared with Turbuhaler® in patients with moderate-to-severe chronic obstructive pulmonary disease in S Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature.The pharmacological approach to the elderly COPD patient.Characteristics of COPD patients initiating treatment with aclidinium or tiotropium in primary care in Catalonia: a population-based study.Incidence, Predictors, and Clinical Implications of Discontinuing Therapy with Inhaled Long-Acting Bronchodilators among Patients with Chronic Obstructive Pulmonary Disease.Factors associated with medication adherence in patients with chronic obstructive pulmonary disease.Describing drivers of and barriers to persistence with tiotropium in patients with chronic obstructive pulmonary disease: a mixed-methods approach.Adherence and Persistence to Long-Acting Anticholinergics Treatment Episodes in Patients With Chronic Obstructive Pulmonary Disease.Adherence to long-acting inhaled therapies among patients with chronic obstructive pulmonary disease (COPD).Tiotropium as part of inhaled polytherapy: adherence and associated health-care utilization.Determinants of Long-Term Persistence with Tiotropium Bromide for Chronic Obstructive Pulmonary Disease.A comparison of medication adherence/persistence for asthma and chronic obstructive pulmonary disease in the United Kingdom.Adherence to inhaled therapy and its impact on chronic obstructive pulmonary disease (COPD)

P2860

Q26823682-5A996EBA-018E-4CE5-8F09-F7C4328100DD Q27348844-D984FF95-D593-430E-8CAD-377A500DB641 Q33646667-F3F7B13A-6223-4182-8AE4-87AF15C3AE14 Q33966009-76C2106C-4129-4EA9-BB07-27C2A6AAEBD6 Q34121263-4305ED7F-9DAD-486F-8855-DBF1C3C4D15B Q34128947-D717EBDF-097A-43A3-8B0B-8742F2F3C845 Q34273638-26171A01-A157-4C02-A202-8B2C3EB4EB72 Q35205369-A9B4EB91-2DE8-4D6E-923A-47B2176045AF Q35208787-28DDCEB3-AD7B-44DC-ADC1-414224D9F474 Q35216376-FECF70F1-36AA-489B-98D5-08B2FD87BCF3 Q36390652-12D72FC4-183B-408B-B222-0DB57BCC3280 Q36642198-B5216666-5C95-4DDB-9A0D-ACBD2F9087F8 Q36858219-A2E28EA8-3C72-4A50-AEED-5F00882C6AA1 Q37115876-5B6973BE-A51A-49B1-8C78-3D44B9A1E919 Q37133820-6979C46A-2CA6-4A09-B50A-EAE3745BD559 Q37310689-F490C7B6-E85F-4FFB-B84D-95ADB0FAEC37 Q37340845-4376A6A4-632F-49B3-85E1-16FFFAEDA7C9 Q37502960-7E5F57B0-130A-4E23-88B5-150D1835097D Q37645807-6C0B73D9-7F4E-428E-B42F-B55A2CF2C7A0 Q37864717-45B22370-969D-4AC3-8252-9398A082AF36 Q38098479-EAFD41A7-8E25-4F3E-83C3-1D914D63EFCF Q38819989-5BA0CC95-5516-495C-A4E5-A3B29C487448 Q40876442-A9407B0A-EEF2-4B1B-B913-D9D2A6F3ED39 Q43744795-F99683D9-5851-485B-A514-ADBB4493C5B4 Q46831428-90DE490A-51BF-4B26-84E6-0E8724D6E5ED Q47816402-566C68FA-EF1D-4316-BE91-CFD00E858577 Q47911959-5BED289F-58D0-4522-8740-0E4FDE4D48B9 Q50601223-7A23BD5C-3655-49F1-8986-05749A0F0103 Q51706078-BA471EB2-592E-417F-877C-865DC96B9746 Q51725664-76CCE692-DB67-4C7B-B4C3-C6FAC2AE06BF Q57809552-8341ABDD-0E7A-4D0A-AF74-2F677168D1A4

P2860

Treatment persistence and compliance with medications for chronic obstructive pulmonary disease

http://www.wikidata.org/entity/Q37212357

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2007

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Treatment persistence and comp ...... obstructive pulmonary disease

@en

Treatment persistence and comp ...... obstructive pulmonary disease.

@nl

type

label

Treatment persistence and comp ...... obstructive pulmonary disease

@en

Treatment persistence and comp ...... obstructive pulmonary disease.

@nl

prefLabel

Treatment persistence and comp ...... obstructive pulmonary disease

@en

Treatment persistence and comp ...... obstructive pulmonary disease.

@nl

P1433

Q37212357-689C6B99-41E4-49E8-87AD-61202EA1F10F

P1476

Q37212357-02703EE9-C822-497A-8265-9CA4394CF65F

P2093

Q37212357-69EDB8B9-FC35-41BC-A100-1902FB58DCC1

Q37212357-7D348180-190D-437B-9B0E-DECD836CA7F4

Q37212357-8A23F63F-7391-484D-93AC-979E4E555327

P2860

Q37212357-0D63DBEA-9107-4F86-9144-BD9146ADC51A

Q37212357-17CD7E7A-6890-4E17-8F34-CDF8C393C19D

Q37212357-25182E12-24AC-44CC-BA13-4A8393B7C34A

Q37212357-34B57D29-BFDF-4F31-B39E-F26A2E2FFBB5

Q37212357-6519A8BC-0AC9-475E-B45B-D17DF2019D90

Q37212357-7416AD9B-9441-4455-A3F5-89E21BD6A277

Q37212357-7D34FA9F-8D00-47F3-B9F0-8865F95A7623

Q37212357-BF961173-2116-4B78-AAFA-BF2B5BE159A4

Q37212357-C07ECAFE-C414-45C2-8A4F-A44A5A8F64FF

Q37212357-C706142A-A2AC-410B-B426-07A44D04CC6D

P304

Q37212357-6A1CA7C5-840F-4467-A589-BEFA8FF2C9D5

P31

Q37212357-2E2C3FE7-1B5F-4959-9A0E-59E7E5F16AA4

P356

Q37212357-E61AC9BF-CAA4-463E-B633-E1AE4CE6356E

P407

Q37212357-9AE6BBC4-7508-4B4C-87E5-F8736E137AB5

P433

Q37212357-C4411A3A-AD4F-4543-A1D0-D44C7DA6DC6D

P478

Q37212357-1B172CED-2B8D-4240-A971-010000357139

P577

Q37212357-089AAF0F-F81A-4A72-91E2-3E4F7F912A77

P698

Q37212357-87F51488-C24E-4330-8E38-9F44112BCE3F

P921

Q37212357-9940F687-CEC1-44D4-87B1-68CE92FC28CC

P932

Q37212357-EE49F92C-90B4-4622-AAF4-5C90C9782F6F

P356

P1433

Canadian Respiratory Journal

P1476

Treatment persistence and comp ...... obstructive pulmonary disease

@en

P2093

Alissa Scalera

http://www.w3.org/2001/XMLSchema#string

Carole Bradley-Kennedy

http://www.w3.org/2001/XMLSchema#string

Joyce A Cramer

http://www.w3.org/2001/XMLSchema#string

P2860

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary

A systematic review of the associations between dose regimens and medication compliance.

Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease--2003.

A randomised controlled comparison of tiotropium nd ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group

Tiotropium: an inhaled anticholinergic for chronic obstructive pulmonary disease.

Results of a naturalistic study of treatment options: switching atypical antipsychotic drugs or augmenting with valproate.

The assessment of refill compliance using pharmacy records: methods, validity, and applications.

Predictors of persistence of use of the novel antidiabetic agent acarbose.

Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies.

Persistence with inhaled corticosteroid therapy in daily practice.

P304

25-29

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2007/161652

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2007-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17315055

http://www.w3.org/2001/XMLSchema#string

P921

chronic obstructive pulmonary disease

P932

2690446

http://www.w3.org/2001/XMLSchema#string